Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections

Kwamena William Coleman Sagoe; Kwabena Obeng Duedu; Francesca Ziga; Afrakoma Adjoa Agyei; Theophilus Korku Adiku; Margaret Lartey; Julius Abraham Addo Mingle; Max Arens

doi:10.1186/s12941-016-0152-2

Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections

Kwamena William Coleman Sagoe^*, Kwabena Obeng Duedu, Francesca Ziga, Afrakoma Adjoa Agyei, Theophilus Korku Adiku, Margaret Lartey, Julius Abraham Addo Mingle, Max Arens

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Citation (SciVal)

Abstract

BACKGROUND: Co-infection of HIV with HBV is common in West Africa but little information is available on the effects of HBV on short-term therapy for HIV patients. A 28 day longitudinal study was conducted to examine short-term antiretroviral therapy (ART) outcomes in HIV infected individuals with HBV co-infection. METHODS: Plasma from 18 HIV infected individuals co-infected with HBV and matched controls with only HIV infection were obtained at initiation, and 7 and 28 days after ART. HIV-1 viral load changes were monitored. Clinical and demographic data were also obtained from patient folders, and HIV-1 drug resistance mutation and subtype analysis performed. RESULTS: The presence of HBV co-infection did not significantly affect HIV-1 viral load changes within 7 or 28 days. The CD4(+) counts on the other hand of patients significantly affected the magnitude of HIV-1 viral load decline after 7 days (rho = -0.441, p = 0.040), while the pre-ART HIV-1 VL (rho = 0.844, p =

Original language	English
Article number	38
Journal	Annals of Clinical Microbiology and Antimicrobials
Volume	15
Issue number	1
DOIs	https://doi.org/10.1186/s12941-016-0152-2 https://doi.org/10.1186/s12941-016-0152-2
Publication status	Published (VoR) - 2 Jun 2016

Keywords

Antiretroviral therapy
Co-infection
Drug resistance
Hepatitis B virus
Human immunodeficiency virus
Short-term therapy

Access to Document

https://www.ncbi.nlm.nih.gov/pubmed/27251610

Cite this

Sagoe, K. W. C., Duedu, K. O., Ziga, F., Agyei, A. A., Adiku, T. K., Lartey, M., Mingle, J. A. A., & Arens, M. (2016). Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections. Annals of Clinical Microbiology and Antimicrobials, 15(1), Article 38. https://doi.org/10.1186/s12941-016-0152-2, https://doi.org/10.1186/s12941-016-0152-2

@article{4d68d28c32b740a6aad7720903ce4603,

title = "Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections",

abstract = "BACKGROUND: Co-infection of HIV with HBV is common in West Africa but little information is available on the effects of HBV on short-term therapy for HIV patients. A 28 day longitudinal study was conducted to examine short-term antiretroviral therapy (ART) outcomes in HIV infected individuals with HBV co-infection. METHODS: Plasma from 18 HIV infected individuals co-infected with HBV and matched controls with only HIV infection were obtained at initiation, and 7 and 28 days after ART. HIV-1 viral load changes were monitored. Clinical and demographic data were also obtained from patient folders, and HIV-1 drug resistance mutation and subtype analysis performed. RESULTS: The presence of HBV co-infection did not significantly affect HIV-1 viral load changes within 7 or 28 days. The CD4(+) counts on the other hand of patients significantly affected the magnitude of HIV-1 viral load decline after 7 days (rho = -0.441, p = 0.040), while the pre-ART HIV-1 VL (rho = 0.844, p = ",

keywords = "Antiretroviral therapy, Co-infection, Drug resistance, Hepatitis B virus, Human immunodeficiency virus, Short-term therapy",

author = "Sagoe, {Kwamena William Coleman} and Duedu, {Kwabena Obeng} and Francesca Ziga and Agyei, {Afrakoma Adjoa} and Adiku, {Theophilus Korku} and Margaret Lartey and Mingle, {Julius Abraham Addo} and Max Arens",

note = "Publisher Copyright: {\textcopyright} 2016 The Author(s).",

year = "2016",

month = jun,

day = "2",

doi = "10.1186/s12941-016-0152-2",

language = "English",

volume = "15",

journal = "Annals of Clinical Microbiology and Antimicrobials",

issn = "1476-0711",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections

AU - Sagoe, Kwamena William Coleman

AU - Duedu, Kwabena Obeng

AU - Ziga, Francesca

AU - Agyei, Afrakoma Adjoa

AU - Adiku, Theophilus Korku

AU - Lartey, Margaret

AU - Mingle, Julius Abraham Addo

AU - Arens, Max

PY - 2016/6/2

Y1 - 2016/6/2

N2 - BACKGROUND: Co-infection of HIV with HBV is common in West Africa but little information is available on the effects of HBV on short-term therapy for HIV patients. A 28 day longitudinal study was conducted to examine short-term antiretroviral therapy (ART) outcomes in HIV infected individuals with HBV co-infection. METHODS: Plasma from 18 HIV infected individuals co-infected with HBV and matched controls with only HIV infection were obtained at initiation, and 7 and 28 days after ART. HIV-1 viral load changes were monitored. Clinical and demographic data were also obtained from patient folders, and HIV-1 drug resistance mutation and subtype analysis performed. RESULTS: The presence of HBV co-infection did not significantly affect HIV-1 viral load changes within 7 or 28 days. The CD4(+) counts on the other hand of patients significantly affected the magnitude of HIV-1 viral load decline after 7 days (rho = -0.441, p = 0.040), while the pre-ART HIV-1 VL (rho = 0.844, p =

AB - BACKGROUND: Co-infection of HIV with HBV is common in West Africa but little information is available on the effects of HBV on short-term therapy for HIV patients. A 28 day longitudinal study was conducted to examine short-term antiretroviral therapy (ART) outcomes in HIV infected individuals with HBV co-infection. METHODS: Plasma from 18 HIV infected individuals co-infected with HBV and matched controls with only HIV infection were obtained at initiation, and 7 and 28 days after ART. HIV-1 viral load changes were monitored. Clinical and demographic data were also obtained from patient folders, and HIV-1 drug resistance mutation and subtype analysis performed. RESULTS: The presence of HBV co-infection did not significantly affect HIV-1 viral load changes within 7 or 28 days. The CD4(+) counts on the other hand of patients significantly affected the magnitude of HIV-1 viral load decline after 7 days (rho = -0.441, p = 0.040), while the pre-ART HIV-1 VL (rho = 0.844, p =

KW - Antiretroviral therapy

KW - Co-infection

KW - Drug resistance

KW - Hepatitis B virus

KW - Human immunodeficiency virus

KW - Short-term therapy

UR - http://www.scopus.com/inward/record.url?scp=84979032189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979032189&partnerID=8YFLogxK

U2 - 10.1186/s12941-016-0152-2

DO - 10.1186/s12941-016-0152-2

M3 - Article

C2 - 27251610

SN - 1476-0711

VL - 15

JO - Annals of Clinical Microbiology and Antimicrobials

JF - Annals of Clinical Microbiology and Antimicrobials

IS - 1

M1 - 38

ER -

Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this